Analysts Remain Bullish on BioMarin Pharmaceutical



Analyst recommendations

Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for BioMarin stock is 1.78 with a target price of $119.35, implying an upside potential of 21.1% over its closing price of $98.58 on September 12.

Article continues below advertisement

Peer ratings

In comparison, peers Voyager Therapeutics (VYGR), Nightstar Therapeutics (NITE), and Audentes Therapeutics (BOLD) have mean ratings of 1.83, 1.43, and 2.14, respectively, and target prices of $31.27, $30.57, and $39.25, respectively.

Valuation metrics

In early 2018, amid the broader market turmoil, BioMarin stock corrected from $92.39 on January 23 to $77.67 on March 1. Subsequently, it steadily climbed to $105.72 on August 7 and then sharply corrected to its current $98 level in September.

The enterprise value of BioMarin is $17.24 billion, and its enterprise-value-to-revenue ratio is 11.98x. Its price-to-sales ratio is 12.17x, and its price-to-book ratio is 6.13x.

Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 2.80x. In comparison, the current ratios of peers Voyager Therapeutics (VYGR), Nightstar Therapeutics (NITE), and Audentes Therapeutics (BOLD) are 6.90x, 9.90x, and 19.10x, respectively.

We’ll take a look at Solid Biosciences’ research pipeline in the next part.


More From Market Realist